drugset / Trial / NCT05493332

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

NCT05493332

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-armed, multicentric, explorative phase II clinical research of conversional therapy with combination of hepatic arterial infusion chemotherapy(HAIC), Donafenib Tosilate and Toripalimab for unresectable hepatocellular carcinoma.

Timeline

Start
2022-09
Primary completion
2023-09
Completion
2024-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Donafenib Small molecule 0.1 g Oral
Subject Leucovorin Small molecule 400 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Subject fluorouracil Small molecule 600 mg/m2 Intravenous